The global non-Hodgkin lymphoma therapeutics market size was valued at USD 6 billion in 2020 and is estimated to surpass USD 12 billion by 2028, expanding at a CAGR of 8% during the forecast period, 2021–2028. The growth of the market is attributed to the rising prevalence of non-lymphomas Hodgkin's (NHL).
Lymphoma is cancer that affects lymphocytes, which are a type of white blood cell. This usually happens in the lymphatic system, bone marrow, lymph nodes, spleen, blood, and other organs. It is one of the most dangerous and life-threatening cancers. Non-Hodgkin's lymphomas are a type of blood cancer that includes a wide range of lymphomas but does not include Hodgkin's lymphomas. NHL ranges from minor to deadly. Night sweats, skin irritation, recurrent high fever, shortness of breath, appetite loss and weight loss, and painless sweating of lymph nodes located throughout the body are all common signs of the disease.
Market Trends, Drivers, Restraints, and Opportunities
- Rising prevalence of non-Hodgkin's lymphomas (NHL) and other cancers, increasing R&D procedures, rising public awareness about the impacts of NHL, and increased medical and healthcare expenditure and infrastructure are estimated to propel the market expansion in the coming years.
- Increasing global market revenue by improving a disorder’s prognosis, due to the modern therapeutics, high cure rates, and effective diagnostic procedures frequently work hand in hand for better treatment outcomes, which individuals are more inclined to accept advanced treatment.
- High cost of NHL medications, as well as the multiple side-effects that are associated with them, are projected to impede the market growth.
- Rigorous regulatory standards and the high cost of R&D and treatment possess as key challenges that can hamper the market expansion during the forecast period.
Scope of the Report
The report on the global non-Hodgkin lymphoma therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Global Non-Hodgkin Lymphoma Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2020
|
|
Historic Data
|
2018–2019
|
|
Forecast Period
|
2021–2028
|
|
Segmentation
|
Types of Therapy (Chemotherapy, Targeted Therapy, Radiation Therapy, Immunotherapy, and Others), Cell Types (T-cell Lymphoma and B-cell Lymphoma), Distribution Channels (Hospital Pharmacies, Drug Stores, Online Pharmacies, and Retail Pharmacies)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Accredo Health Group Inc.; Baxter International Inc.; AstraZeneca; Bayer AG; Eli Lilly and Co.; Celgene Corp.; Teva Pharmaceuticals Industries Ltd; F. Hoffmann La-Roche Ltd.; Spectrum Pharmaceuticals; GlaxoSmithKline PLC; Seattle Genetics Inc.; Novartis; and Pfizer
|
Global Non-Hodgkin Lymphoma Therapeutics Market Segment Insights
Radiation therapy segment is projected to account for a major key share
Based on types of therapy, the global non-Hodgkin lymphoma therapeutics market is segmented into chemotherapy, targeted therapy, radiation therapy, and others. The radiation therapy segment is expected to account for a key share of the market during the forecast period owing to the use of high-energy beams or particles to kill cancer cells. It can be administered from an external source (external beam radiation) or from within the body (brachytherapy). Radiation treatments are usually administered five days a week for a few weeks.
When this type of lymphoma is only discovered in one place of the body, radiation therapy is most successful. For improved results in advanced lymphomas, radiation therapy is utilized in combination with chemotherapy. It mostly aids in the relief of lymphoma-related symptoms.
B-cell Lymphoma segment expected to register at a significant pace
On the basis of cell types, the market is bifurcated into T-cell lymphoma and B-cell lymphoma. The B-cell lymphoma is expected to constitute a key share of the market in the coming years due to a majority of non-Hodgkin lymphoma cases and is expected to maintain its market share over the forecast period, which accounts for B-cell lymphoma's dominance in the global market for non-Hodgkin lymphoma treatment.
On the other hand, the T-cell lymphoma segment is anticipated to expand at a rapid pace during the forecast period owing to the fairly rare appearance of T-cell lymphoma, which results in a lower number of patients than B-cell lymphoma, which is likely to restrain the segment's expansion.
Hospital Pharmacies segment is anticipated to expand at a substantial CAGR
In terms of distribution channels, the global non-Hodgkin lymphoma therapeutics market is fragmented into hospital pharmacies, drug stores, online pharmacies, and retail pharmacies. The hospital pharmacies are expected to hold a key share of the market during the forecast period owing to the majority of medications used to treat lymphoma can only be given intravenously. This necessitates the use of qualified medical personnel to ensure that the treatment instructions are followed correctly. This ensures that medications are administered safely and also that clinical outcomes are favourable.
However, the online pharmacies segment is anticipated to expand at a rapid pace during the forecast period due to several advantages such as the convenience of completing prescriptions from the comfort of one's own home.
Asia Pacific is expected to dominate the market
On the basis of regions, the market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. Asia Pacific is anticipated to expand at a healthy CAGR during the forecast period. The regional market growth can be attributed to the result of variables such as increased access to healthcare services in the region and an increase in the prevalence of NHL. Many manufacturing companies are investing in developing novel drug therapies to fulfill the growing demand for treatments as the incidence and prevalence of non-Hodgkin lymphoma rise year after year. However, North America is expected to exhibit a rapid growth rate in the coming years due to technological advancements and rising NHL incidences in the country.
Segments
Segments Covered in the Report
The global non-Hodgkin lymphoma therapeutics market has been segmented on the basis of
Types of Therapy
- Chemotherapy
- Targeted Therapy
- Radiation Therapy
- Immunotherapy
- Others
Cell Types
- T-cell Lymphoma
- B-cell Lymphoma
Distribution Channels
- Hospital Pharmacies
- Drug Stores
- Online Pharmacies
- Retail Pharmacies
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Accredo Health Group Inc.
- Baxter International Inc.
- AstraZeneca; Bayer AG
- Eli Lilly and Co.
- Celgene Corp.
- Teva Pharmaceuticals Industries Ltd
- F. Hoffmann La-Roche Ltd.
- Spectrum Pharmaceuticals
- GlaxoSmithKline PLC
- Seattle Genetics Inc.
- Novartis
- Pfizer
Competitive Landscape
Key players competing in the global non-Hodgkin lymphoma therapeutics market include Accredo Health Group Inc.; Baxter International Inc.; AstraZeneca; Bayer AG; Eli Lilly and Co.; Celgene Corp.; Teva Pharmaceuticals Industries Ltd; F. Hoffmann La-Roche Ltd.; Spectrum Pharmaceuticals; GlaxoSmithKline PLC; Seattle Genetics Inc., Novartis; and Pfizer.
Request For Customization
Enquiry Before Buying
Speak With Analyst
